Abstract
Antibody-drug conjugates (ADCs) are new modality of anticancer therapeutics. To enhance the translation, three components of an ADC drug—antibody, linker, and cytotoxin— need to be carefully optimized. The selection of antibody and target plays a key role in the success of ADCs. Ideal targets are the antigens which are expressed only on tumor cells. As one of crucial component, linkers such as cleavable linkers and noncleavable linkers have been explored. Finally, the highly effective payloads including tubulin inhibitors and DNA-damaging antibiotics have been discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254–62. https://doi.org/10.1016/S1470-2045(16)30030-4.
Lin L, Ding Q, Tang Q, et al. Antibody-drug conjugates and their application in the treatment of hematological malignancies. Acta Pharm Sin. 2012;47(10):1287–96.
Jen EY, Ko CW, Lee JE, et al. FDA approval: Gemtuzumab ozogamicin for the treatment of adults with newly-diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res. 2018;24:3242. https://doi.org/10.1158/1078-0432.CCR-17-3179.
Pan LQ, Wang HB, **e ZM, et al. Novel conjugation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with monomethyl auristatin E for efficient antitumor drug delivery. Adv Mater. 2013;25(34):4718–22.
Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009;69:2358–64.
Lewis-Phillips GD, Li G, Dugger DL. Targeting HER2-postive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;6:9280–90.
Barriuso B, Antolín P, Arias FJ, et al. Anti-human endoglin (hCD105) immunotoxin— containing recombinant single chain ribosome-inactivating protein musarmin 1. Toxins. 2016;8(6):184.
Kalim M, Chen J, Wang S, et al. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther. 2017;11:2265–76.
Tsuchikama K, An ZQ. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33–46.
Jain N, Smith SW, Ghone S, et al. Current ADC linker chemistry. Pharm Res. 2015;32:3526–40.
Lai J, Wang Y, Wu S, et al. Elimination of melanoma by sortase A generated TCR like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1. Biomaterials. 2018;178:158–69.
Axup JY, Bajjuri KM, Ritland M, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci USA. 2012;109:16101–6.
Zhu GD, Fu YX. Design of next generation antibody drug conjugates. Acta Pharm Sin. 2013;48(7):1053–70.
Chudasama V, Maruani A, Caddick S. Recent advances in the construction of antibody-drug conjugates. Nat Chem. 2016;8:114–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Zhan, J. (2023). Antibody-Drug Conjugates: Basic Concepts and Structures. In: Chen, S., Zhan, J. (eds) Antibody-Drug Conjugates and Cellular Metabolic Dynamics. Springer, Singapore. https://doi.org/10.1007/978-981-19-5638-6_1
Download citation
DOI: https://doi.org/10.1007/978-981-19-5638-6_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-5637-9
Online ISBN: 978-981-19-5638-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)